Introduction {#s1}
============

The rapid expansion of highly active antiretroviral therapy (HAART) in resource-limited settings has markedly improved the prognosis of patients infected with HIV [@pone.0054917-Zhang1]. These benefits, however, can be compromised by the development of HIV drug resistance (HIVDR) [@pone.0054917-Zhang2], [@pone.0054917-DeGruttola1], making treatment less effective [@pone.0054917-DAquila1], [@pone.0054917-Zolopa1]. Drug resistance is increasingly problematic in developing countries, which rely heavily on first-line generic drugs and have very limited second-line treatment options. Factors associated with the development of drug resistance include inadequate suppression of virus replication due to suboptimal treatment regimens, difficulty adhering to complex and toxic regimens, and initiation of therapy late in the course of HIV infection [@pone.0054917-Boden1]. To understand better the prevalence and risk factors of HIVDR in China, three cross-sectional surveys were conducted over time by the Chinese National HIVDR Surveillance and Monitoring Network.

Methods {#s2}
=======

Study Design and Setting {#s2a}
------------------------

The China National Free Antiretroviral Treatment Program [@pone.0054917-Zhang1], [@pone.0054917-Zhang2], [@pone.0054917-Ma1], [@pone.0054917-Zhang3] was initiated in 2002 among former plasma donors who contracted the virus in the mid-1990s [@pone.0054917-Dou1], then expanded beginning in 2003 to treat all HIV-infected patients across mainland China who met the national treatment guidelines of: (1) CD4 cell count \<350/mm^3^ (increased from 200/mm^3^ in 2008); (2) total lymphocyte count \<1,200/mm^3^; or (3) World Health Organization (WHO) stage III or IV disease [@pone.0054917-Dou1], [@pone.0054917-Zhang4]. First-line HAART regimens consist of \[azidothymidine (AZT) or stavudine (D4T)\] + \[didanosine (DDI) or lamivudine (3TC)\] + \[nevirapine (NVP) or efavirenz (EFV)\]. AZT, D4T, DDI, and NVP are generically produced in China, whereas 3TC and EFV are branded drugs that became available in 2005. Second-line drugs, including tenofovir (TDF) and lopinavir/ritonovir (LPV/r), were introduced in limited fashion since 2008 but have not yet scaled up widely.

Patient Recruitment Algorithms for Cross-sectional Surveys {#s2b}
----------------------------------------------------------

The Chinese National HIVDR Surveillance and Monitoring Network consists of 4 central laboratories (National Center for AIDS/STD Control and Prevention \[NCAIDS\], Shanghai Municipal Center for Disease Control and Prevention (CDC), Chinese Medical University Center for AIDS Research, and Institute of Microbiology and Epidemiology of the Chinese Academy of Military Medical Sciences) and laboratories from 30 provincial CDCs. Cross-sectional surveys were conducted nationally among HIV-infected adults ≥18 years in 2004, 2005, and 2006. For treatment-experienced patients, screening and recruitment into the study was performed per [Figure 1](#pone-0054917-g001){ref-type="fig"}. In 2006, in addition to this algorithm, all patients previously surveyed in 2004 or 2005 and could be located were also followed-up. County was the minimal sampling unit and sampling proportion was reverse with the number of treated patients in the county so that the strategy could result in a representative population. After informed consent, all patients completed a standardized questionnaire for demographics, HIV risk factors, and ART history. Treatment adherence was measured by self-reported missed doses in the previous month. A blood sample was collected for CD4 cell count and HIV viral load (VL). Genotypic resistance testing was performed if VL was ≥1000 copies/mL.

![Patient recruitment algorithm for antiretroviral therapy experienced patients screened for the 2004, 2005, and 2006 cross-sectional surveys.](pone.0054917.g001){#pone-0054917-g001}

All subjects provided written informed consent to participate in this study. The institutional review board (IRB) of the NCAIDS, China CDC approved this study.

Laboratory Analysis {#s2c}
-------------------

CD4 cell count was measured by flow cytometry in provincial CDCs. The four state central laboratories performed the HIV VL and drug resistance tests. Plasma HIV-1 RNA was quantified with real-time nucleic acid sequence based amplification (NASBA; NucliSense Easy Q, bioMerieux, France) or Amplicor HIV-1 monitor test (COBAS®, Roche Applied Science, Germany). In samples with VL ≥1000 copies/ml, HIVDR genotyping was performed by in-house polymerase chain reaction (PCR) as previously described [@pone.0054917-Zhong1], [@pone.0054917-Liao1]. The resulting fragment of the HIV-1 *pol* gene (protease, amino acids 1--99; and part of reverse transcriptase, amino acids 1--252) was analyzed for drug resistance mutations using the Stanford HIV Drug Resistance Database (<http://hivdb.stanford.edu>). We included mutation results that conferred low-, intermediate-, and high- level resistance [@pone.0054917-Liu1].

Statistical Analysis {#s2d}
--------------------

For patients sampled more than once across the three surveys, data from the first survey showing drug resistance were included in this analysis. If no drug resistance was identified, data from the last survey were included. Data from the three surveys were combined. Demographic variables were described with descriptive statistics. Risk factors for developing HIVDR were analyzed by logistic regression. Variables associated with resistance in univariate analyses (*p*-value\<0.05) and those clinically meaningful were included in the multivariable regression model. Tests were two-sided, with a *p*-value\<0.05 indicating statistical significance.

Results {#s3}
=======

Demographic Characteristics {#s3a}
---------------------------

The number of patients in each of the three cross-sectional surveys from 2004, 2005 and 2006 were 1051, 2755, and 2689, respectively. 3667 were unique individuals, with 2826 treatment-experienced and 841 treatment-naïve. Only the treatment-experienced patients were included in our analysis, whose characteristics were shown in [Table 1](#pone-0054917-t001){ref-type="table"}. The patients were primarily farmers who were former plasma donors from Henan, Anhui and Hubei province. This is the cohort that has been treated the longest in China. 47.8% was male, mean age was 39.5±9.8, 85.0% was Han ethnicity, 53.9% had primary school education or less. The distribution of subjects and subtype according to province was shown in [Figure 2](#pone-0054917-g002){ref-type="fig"}.

![Distribution of subjects and subtype according to province.](pone.0054917.g002){#pone-0054917-g002}
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###### Factors associated with HIVDR among ART treated patients.

![](pone.0054917.t001){#pone-0054917-t001-1}

  Variable                                                     Number   HIV drug resistance*N* (%)   Crude OR(95% CI)   *P-* *value*   Adjusted OR (95% CI)   *P-* *value*
  ----------------------------------------------------------- -------- ---------------------------- ------------------ -------------- ---------------------- --------------
  Total                                                         2826            543(19.2)                                                                    
  Sex                                                                                                                                                        
  Male                                                          1475            274(18.6)                                                                    
  Female                                                        1351            269(19.9)              1.1(0.9,1.3)         0.37                             
  Age (Years)                                                                                                                                                
  ≤30                                                           429              62(14.5)                                                                    
  31--50                                                        2006            395(19.7)              1.5(1.1,1.9)         0.12                             
  \>50                                                          391              86(22.0)              1.7(1.2,2.4)        \<0.01                            
  Ethnicity                                                                                                                                                  
  Han                                                           2403            493(20.5)                                                                    
  Minorities                                                    423              50(11.8)              0.5(0.4,0.7)        \<0.01                            
  Married                                                                                                                                                    
  Yes                                                           2097            414(19.7)                                                                    
  No                                                            729             129(17.7)             (0.9,1.7,1.1)         0.23                             
  Education                                                                                                                                                  
  Primary school or less                                        1524            355(23.3)                                                                    
  Junior high school or more                                    1302            188(14.4)              0.6(0.5,0.7)        \<0.01                            
  Farmer                                                                                                                                                     
  Yes                                                           1354            313(23.1)                                                                    
  No                                                            1472            230(15.6)              0.6(0.5,0.7)        \<0.01                            
  HIV transmission route                                                                                                                                     
  Sexual intercourse                                            618              59(9.6)                                                                     
  Blood/plasma transmission                                     1741            424(24.4)              3.1(2.3,4.1)        \<0.01                            
  Drug injection                                                226              27(12.0)              1.3(0.8,2.1)         0.31                             
  Other                                                         241              33(13.7)              1.5(0.9,2.4)         0.08                             
  Initial HAART Regimen                                                                                                                                      
  AZT/D4T+DDI+NVP/EFV                                           1314            355(27.0)                                                                    
  AZT/D4T+3TC+NVP/EFV                                           1131             105(9.3)              0.3(0.2,0.4)        \<0.01          0.5(0.3,0.6)          \<0.01
  Other regimens                                                381              83(21.8)              0.8(0.6,1.0)         0.04           0.9(0.7,1.3)           0.73
  Duration of HAART (months)                                                                                                                                 
  0--11                                                         996             148(14.9)                                                                    
  12--23                                                        852             176(20.7)              1.5(1.2,1.9)        \<0.01          1.4(1.1,1.8)           0.01
  24--35                                                        679             157(23.1)              1.7(1.3,2.2)        \<0.01          1.3(1.0,1.8)           0.05
  ≥36                                                           299              62(20.7)              1.5(1.1,2.1)         0.02           1.1(0.8,1.6)           0.52
  Missing doses in the past month                                                                                                                            
  No                                                            2465            449(18.2)                                                                    
  Yes                                                           268              69(25.8)              1.6(1.2,2.1)        \<0.01          1.5(1.1,2.1)          \<0.01
  Discontinuation                                                93              25(26.9)              1.7(1.0,2.6)        \<0.01          0.9(0.7,1.3)           0.74
  ART drug distribution location                                                                                                                             
  County hospital or CDC                                        1211            142(11.7)                                                                    
  Township hospital or village clinic or medication monitor     1615            401(24.8)              2.5(2.1,3.1)        \<0.01          1.4(1.1,1.8)           0.02
  CD4 cell account at survey                                                                                                                                 
  ≥350                                                          1078            133(12.3)                                                                    
  200--349                                                      862             162(18.8)              1.6(1.3,2.1)        \<0.01          2.1(1.6,2.7)          \<0.01
  50--199                                                       738             189(25.6)              1.4(1.9,3.1)        \<0.01          3.7(2.9,4.9)          \<0.01
  \<50                                                          148              59(39.9)              4.7(3.2,6.9)        \<0.01          5.9(3.9,8.8)          \<0.01
  Changing Regimens                                                                                                                                          
  No                                                            2387            458(19.2)                                                                    
  Yes(3TC based Regimens)                                       298              54(18.1)              0.9(0.7,1.3)         0.66                             
  Yes(DDI based Regimens)                                       141              31(22.0)              1.2(0.8,1.8)         0.41                             
  Province                                                                                                                                                   
  Others                                                        1396            145(10.4)                                                                    
  Henan, Anhui and Hubei                                        1430            398(27.8)              3.3(2.7,4.1)        \<0.01          2.2(1.7,2.9)          \<0.01

Use of HIV ART Drugs and Virologic and Immunologic Profiles {#s3b}
-----------------------------------------------------------

Initial HAART regimens used were AZT+DDI+NVP (24.2%), D4T+DDI+NVP (17.6%), AZT+DDI+EFV (3.1%), D4T+DDI+EFV(1.6%), AZT+3TC+NVP (13.0%), D4T+3TC+NVP (21.1%), AZT+3TC+EFV (3.0%), D4T+3TC+EFV (2.9%), and other (13.5%). DDI-based regimens were used in the earlier years but those were switched to lamivudine starting in 2005, when lamivudine became widely available [@pone.0054917-Dou2]. At the time of their survey, the median duration of treatment was 17.4 months (interquartile range \[IQR\], 8.6--28.4), with 954 (33.8%) of treated patients having a VL ≥1000 copies/ml. Of these, 543 (56.9%) had resistance mutations identified, including 294 (54.1%) with dual-class resistance.

Prevalence of HIV Drug Resistance Mutations {#s3c}
-------------------------------------------

Among those with HIVDR mutations identified, 522/543 (96.1%) treatment-experienced patients were resistant to non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs ([Table 2](#pone-0054917-t002){ref-type="table"}). 311/543(57.3%) patients had HIV-1 with resistance mutations to nucleoside reverse transcriptase inhibitors (NNRTIs) 15/543 (2.8%) had major PI resistance mutations identified. All of them had received protease inhibitors. The most common NNRTI mutations occured at positions 103 and 181 in reverse transcriptase (RT) region; NRTI mutations were most common at condons 215 and 184 in RT region; and PI mutations were most frequently seen at condon 82 in protease (PR) region.

10.1371/journal.pone.0054917.t002

###### HIV detectable drug limiting resistance mutations among 543 patients with plasma HIV-1 RNA concentrations ≥1000 copies/ml and drug resistance.

![](pone.0054917.t002){#pone-0054917-t002-2}

  Mutation alleles    Number   Percentage
  ------------------ -------- ------------
  NNRTI (total)        522        96.1
  K103H/N/S/T          287        52.9
  Y181C/I/V            211        38.9
  G190A/S/E/T          141        26.0
  K101E/H/P             49        9.0
  Y188C/H/L             29        5.3
  V106A/M               21        3.9
  K238T                 11        2.0
  F227L                 14        2.6
  P225H                 6         1.1
  M230L                 2         0.4
  V179F                 5         0.9
  L100I                 1         0.2
  E138K/Q               3         0.6
  A98G                  11        2.0
  NRTI (total)         311        57.3
  T215F/I/S/V/Y/       156        28.7
  M184I/V              100        18.4
  D67G/N                92        16.9
  M41L                  84        15.5
  K70E/G/R              64        11.8
  L210W                 54        9.9
  K219E/N/Q             54        9.9
  K65R                  29        5.3
  Q151L/M               26        4.8
  V75A/M/T              19        3.5
  T69D/I                17        3.1
  L74V/I                16        2.9
  Y115F                 1         0.2
  PI (total)            15        2.8
  V82T/A/F              4         0.7
  I54IV                 3         0.6
  G73C                  1         0.2
  N88D                  1         0.2
  I50IV                 1         0.2
  I54S                  1         0.2
  I84IV                 1         0.2
  L90M                  1         0.2
  V32I                  1         0.2
  M46I                  1         0.2

Risk Factors for HIV Drug Resistance {#s3d}
------------------------------------

The risk factors for HIVDR that were significantly in the univariate logistic regression analysis were considered for inclusion in the multivariate logistic regression. In the multivariate logistic regression model ([Table 1](#pone-0054917-t001){ref-type="table"}), the factors significantly associated with drug resistance were province (compared to other provinces: Henan, Anhui and Hubei adjusted odds ratio \[AOR\] 2.2, 95% confidence interval \[CI\] 1.7--2.9); Duration of HAART (compared to less than 12 months: 12--23 AOR 1.4, 95% CI 1.1--1.8, 24--35 AOR 1.3, 95% CI 1.0--1.8, ≥36 AOR 1.1, 95% CI 0.8--1.6); CD4 cell count at survey (compared to CD4≥350/ul: CD4 200--349 AOR 2.1, 95% CI 1.6--2.7, CD4 50--199 AOR 3.7, 95% CI 2.9--4.9, CD4 0--49/ul AOR 5.9, 95% CI 3.9--8.8); ART drug distribution location(compared with county hospital or CDC, AOR 1.4, 95% CI 1.1--1.8) and missing doses in the past month (compared to not missing any doses: AOR 1.5, 95% CI 1.1--2.1, discontinuation: AOR 0.9, 95% CI 0.7--1.3). Compared to didanosine-based regimens, lamivudine-based regimens were protective against developing drug resistance (AOR 0.5, 95% CI 0.3--0.6).

Discussion {#s4}
==========

This analysis of data from the Chinese National HIVDR Surveillance and Monitoring Network showed that among 2826 treatment-experienced patients, 33.8% had a viral load ≥1000 copies/mL and 19.2% had resistance mutations identified, virtually all with NNRTI mutations and two-thirds with NRTI mutations. Patients at the greatest risk of HIVDR were those who received care at township hospitals or village clinics; from Henan, Hubei, or Anhui; began with low baseline CD4 cell counts; started with a didanosine-based regimen; and missed doses in the previous month.

Of note, among the 954 patients with VL ≥1000 copies/mL and virus successfully sequenced, 411 (43.1%) had no resistance mutations identified, among whom 23 (5.6%) had stopped treatment; compared with 9 (1.7%) in 543 patients with mutations, this suggests that poor adherence continues to be a significant problem. Among those with mutations, the actual resistance mutations identified are not surprising for a developing country treatment program based on NRTIs and NNRTIs, with second-line PI regimens not yet scaled up. Of concern, among 543 treatment-experienced patients with drug resistance mutations, 54.1% harbored dual-class resistance. Other studies from low and middle-income countries have found a similar pattern [@pone.0054917-Garrido1]. M184I/V and K103N were the most prevalent NRTI and NNRTI mutations in our study. M184I/V confers resistance to lamivudine, which is also often the first mutation to develop in patients receiving partially suppressive triple combination therapy including lamivudine [@pone.0054917-Tisdale1]. Of note, 12.5% (68/543) of the patients had ≥3 Thymidine analogues Mutations (TAMs), which confer to resistance to all NRTIs. K103N is one of the most clinically important NNRTI resistance mutations, causing 20- to 50-fold resistance to most available NNRTIs [@pone.0054917-Casado1], [@pone.0054917-Joly1], with its high frequency not surprising given the prevalent use of nevirapine in China. Fortunately, each patient with resistance to PI had a single major PI mutation, and none of patients were resistant to LPV/r, which is an important component of second line regimens.

Among treatment-experienced patients, adjusted risk factors for HIVDR included didanosine-based regimens (compared to lamivudine-based), care received at township hospital or village clinic, poor adherence and low baseline CD4 counts. Two factors unique to China were provinces, particularly Henan, Hubei, and Anhui, and plasma donors. They likely have more HIVDR than other areas because they are the center of the plasma donor HIV epidemic in the early-mid 1990s [@pone.0054917-Dou1] and consequently the places where HIV treatment were first scaled up in China [@pone.0054917-Zhang2]. However, their increased HIVDR risk of 2.2 (95% CI 1.1--2.1) compared to other provinces is independent of treatment duration and route of transmission. A Chinese national survey had shown that treatment-naive HIV/AIDS patients had a low prevalence of primary resistance (3.8%), with no significant differences among the three high risk groups (former blood and plasma donors, sexually infected individuals, and intravenous drug users) [@pone.0054917-Liao1]. Therefore, the higher rate of HIVDR in these provinces is not due to exposure to suboptimal therapies prior to cART treatment through the National Free Antiretroviral Treatment Program. In addition, our findings show that patients and healthcare providers from poor, rural areas, such as those from these provinces, were significantly more likely to have HIVDR than those received care in county hospital or CDC, where medical resources may be limited and staff members may have lower levels of education and less advanced technology available [@pone.0054917-Ruan1].

This analysis of HIVDR by the Chinese National HIVDR Surveillance and Monitoring Network is notable for several reasons. First, the significant proportion of patients in virologic failure but without resistance mutations identified and the lag time between time to virologic failure and time to HIVDR suggest that poor treatment adherence continues to play a major role in the development of HIVDR. Second, a significantly higher risk of HIVDR was noted among treatment-experienced patients from Henan, Hubei, and Anhui. This demonstrates that rates and patterns of HIVDR are not constant across China and that local factors play a significant role in the development of HIVDR. In-depth analyses of these provinces are needed to understand better these local factors and how to respond to them. In addition, baseline HIVDR testing should be considered before initiating treatment in patients from these provinces. Finally, this analysis underscores the need to expand access to newer antiretroviral drugs in China, including new HIV drug classes. With increasing rates of HIVDR and second-line therapy slowly scaling up, the need for future additional treatment options is clear and must be a priority in China's efforts to control HIV/AIDS.
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